BRUSSELS – 3 October 2013 – COCIR today announces that Theraclion, a French medical device company set up in 2004, has become a corporate member.
Theraclion has designed and marketed Echopulse, ultimate high technology equipment which combines high intensity focused ultrasound (HIFU) device with real-time ultrasound imaging monitoring for the treatment of the breast fibroadenomas and the thyroid nodules.
This treatment, named “echotherapy™” is a convenient alternative to surgery, allowing a non-invasive, scarless and ambulatory procedure.
Stefano Vagliani, Theraclion’s CEO said, “We have decided to join COCIR to benefit from the trade association’s activities, as they have demonstrated great advancements in the fields of Technical and Regulatory Affairs and Market Intelligence. In particular, we are looking forward to benefitting from the support of COCIR’s China Desk in Beijing to achieve prompt registration of our products in one of the largest markets worldwide”.
Nicole Denjoy, COCIR Secretary General, added “COCIR is delighted to welcome Theraclion to its corporate membership, as this French SME is highly innovative. COCIR is happy to support, share its competences and network with such a company and to facilitate the expansion of its business in countries of interest”.
For more information, contact:
COCIR Secretary General
Tel: +32 (0)2 706 8961
COCIR Communications Advisor
Tel: +32 (0)496 116198
Note to the Editor
Theraclion is a French company, founded in 2004. Theraclion specializes in high-technology medical devices using High-Intensity-Focused-Ultrasound (HIFU).
Relying on the latest engineering technologies and processes, Theraclion offers an innovative solution associating HIFU therapy and monitoring by ultrasound imaging for a safe and efficient non-invasive ablation of breast fibroadenoma and thyroid nodules. The company is headquartered in Malakoff, France.